Alaunos Therapeutics, Inc. Receives Nasdaq Delisting Notice Due to Stockholders’ Equity Shortfall

Key Points:

• Alaunos Therapeutics, Inc. (NASDAQ: TCRT) received a written notice from The Nasdaq Stock Market LLC on April 9, 2026, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1).
• The rule requires a minimum of \$2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market.
• Alaunos reported stockholders’ equity of \$2,153,000 in its Annual Report for the fiscal year ended December 31, 2025—falling below the required threshold.
• The company also does not meet alternative continued listing standards:
  • Market value of listed securities of at least \$35 million
  • Net income from continuing operations of \$500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years
• Alaunos has 45 calendar days from April 9, 2026 (until May 26, 2026) to submit a plan to Nasdaq outlining actions to regain compliance.
• If Nasdaq accepts the plan, the company may be granted up to 180 calendar days from the date of the notice to demonstrate compliance.
• Nasdaq will evaluate factors including the company’s ability to maintain stockholders’ equity compliance for 12 months, past compliance history, reasons for current non-compliance, other corporate events, financial condition, and public disclosures.
• If Alaunos’ plan is not accepted, or if compliance is not regained within the extension period, the company can request a hearing before an independent Nasdaq panel, which would temporarily stay any suspension or delisting action.

Important Information for Shareholders:

• This notice is potentially price-sensitive and may affect share values, as a failure to regain compliance could lead to delisting from the Nasdaq Capital Market.
• Delisting may significantly impact liquidity and marketability of Alaunos shares, as well as limit access to capital markets.
• The company is currently evaluating potential actions to regain compliance, but there is no assurance that the plan will be accepted or that compliance will be achieved within any extension period.
• If the plan is not accepted or compliance is not regained, Alaunos may pursue a hearing, which temporarily prevents delisting.
• Trading in Alaunos securities is expected to continue as a result of this disclosure, provided all required announcements are made in a timely manner.

Details for Investors:

• Alaunos Therapeutics, Inc. is incorporated in Delaware and is headquartered at 501 E Las Olas Blvd, Suite 300, Fort Lauderdale, FL 33301.
• The company’s common stock, par value \$0.001 per share, trades under the symbol TCRT on the Nasdaq Stock Market.
• The company’s Annual Report on Form 10-K for the year ended December 31, 2025, reflects the financial shortfall triggering this notice.
• Alaunos is not classified as an emerging growth company and has not elected extended transition periods for new accounting standards.
• The CEO signed this report on April 15, 2026.

Potential Share Price Impact:

• The Nasdaq delisting notice is material and price-sensitive. Investors should closely monitor subsequent disclosures, including the compliance plan and potential outcomes.
• Uncertainty regarding continued listing may lead to increased volatility and downward pressure on the share price until the issue is resolved.
• Investors are advised to consider the risks associated with possible delisting, including decreased liquidity, potential for trading on less liquid over-the-counter markets, and impacts on institutional investment.

Disclaimer:
This article is based on publicly available SEC filings and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult a financial advisor before making any investment decisions. Alaunos Therapeutics’ compliance with Nasdaq listing requirements remains uncertain, and future developments may materially affect the company’s share price and market position.

View Alaunos Therapeutics, Inc. Historical chart here